Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.

Autor: Tian XP; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Huang WJ; Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China., Huang HQ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Liu YH; Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China., Wang L; Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China., Zhang X; Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China., Lin TY; Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China., Rao HL; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China., Li M; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China., Liu F; Department of Pathology, The First People's Hospital of Foshan, Foshan, China., Zhang F; Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China., Zhong LY; Department of Hematology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China., Liang L; Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Lan XL; Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China., Li J; Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Liao B; Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Li ZH; Department of Oncology, Sun-Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China., Tang QL; Department of Oncology, Sun-Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China., Liang Q; Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Shao CK; Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Zhai QL; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Cheng RF; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Sun Q; Department of Pathology, Hematological hospital of Chinese Academy of Medical Sciences, Tianjin, China., Ru K; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Gu X; Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Lin XN; Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Yi K; Department of Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, China., Shuang YR; Department of Hematology, Jiangxi Provincial Cancer Hospital, Nanchang, China., Chen XD; Department of Pathology, General Hospital of Guangzhou Military Command of PLA, Guangzhou, China., Dong W; Department of Hematology, Shunde Hospital of Southern Medical University, Shunde, China., Sang W; Department of Hematology, The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Sun C; Department of Pathology, The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Liu H; Department of Pathology, The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Zhu ZG; Department of Hematology and Oncology, Guangzhou First People's Hospital, Guangzhou, China., Rao J; Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China., Guo QN; Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing, China., Zhou Y; Department of Medical Oncology, Jiangmen Central Hospital, Jiangmen, China., Meng XL; Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China., Zhu Y; Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China., Hu CL; Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, China., Jiang YR; Department of Hematology, The First People's Hospital of Dongguan, Dongguan, China., Zhang Y; Department of Oncology, Affiliated hospital of Guangdong Medical University, Guangzhou, China., Gao HY; Department of Pathology, Guangdong Province Hospital for Women and Children Health Care, Guangzhou, China., He WJ; Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China., Xia ZJ; Department of Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China., Wu CL; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhang MY; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Wang HY; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Xie D; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. xiedan@sysucc.org.cn., Cai QQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. caiqq@sysucc.org.cn.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. caiqq@sysucc.org.cn.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2019 Oct; Vol. 33 (10), pp. 2454-2465. Date of Electronic Publication: 2019 Apr 05.
DOI: 10.1038/s41375-019-0466-0
Abstrakt: New prognostic factors are needed to establish indications for haematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) for T-cell lymphoblastic lymphoma (T-LBL) patients. We used microarray to compare T-LBL tissue samples (n = 75) and fetal thymus tissues (n = 20), and identified 35 differentially expressed miRNAs. Using 107 subjects as the training group, we developed a five-miRNA-based classifier to predict patient survival with LASSO Cox regression: lower risk was associated with better prognosis (disease-free survival (DFS): hazard ratio (HR) 4.548, 95% CI 2.433-8.499, p < 0.001; overall survival (OS): HR 5.030, 95% CI 2.407-10.513, p < 0.001). This classifier displayed good performance in the internal testing set (n = 106) and the independent external set (n = 304). High risk was associated with more favorable response to HSCT (DFS: HR 1.675, 95% CI 1.127-2.488, p = 0.011; OS: HR 1.602, 95% CI 1.055-2.433, p = 0.027). When combined with ECOG-PS and/or NOTCH1/FBXW7 status, this classifier had even better prognostic performance in patients receiving HSCT (DFS: HR 2.088, 95% CI 1.290-3.379, p = 0.003; OS: HR 1.996, 95% CI 1.203-3.311, p = 0.007). The five-miRNA classifier may be a useful prognostic biomarker for T-LBL adults, and could identify subjects who could benefit from HSCT.
Databáze: MEDLINE
Externí odkaz: